GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $3.45 billion. The enterprise value is $3.43 billion.
| Market Cap | 3.45B |
| Enterprise Value | 3.43B |
Important Dates
The next estimated earnings date is Tuesday, October 28, 2025, before market open.
| Earnings Date | Oct 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 28.73 million shares outstanding. The number of shares has increased by 9.34% in one year.
| Current Share Class | 28.73M |
| Shares Outstanding | 28.73M |
| Shares Change (YoY) | +9.34% |
| Shares Change (QoQ) | +5.71% |
| Owned by Insiders (%) | 1.56% |
| Owned by Institutions (%) | 92.81% |
| Float | 20.47M |
Valuation Ratios
The trailing PE ratio is 2,480.04 and the forward PE ratio is 56.06. GeneDx Holdings's PEG ratio is 1.65.
| PE Ratio | 2,480.04 |
| Forward PE | 56.06 |
| PS Ratio | 9.26 |
| Forward PS | 7.66 |
| PB Ratio | 12.45 |
| P/TBV Ratio | 39.45 |
| P/FCF Ratio | 4,159.77 |
| P/OCF Ratio | 265.10 |
| PEG Ratio | 1.65 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 115.98, with an EV/FCF ratio of 4,135.46.
| EV / Earnings | 2,441.28 |
| EV / Sales | 9.47 |
| EV / EBITDA | 115.98 |
| EV / EBIT | 480.80 |
| EV / FCF | 4,135.46 |
Financial Position
The company has a current ratio of 2.87, with a Debt / Equity ratio of 0.41.
| Current Ratio | 2.87 |
| Quick Ratio | 2.56 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 3.12 |
| Debt / FCF | 137.81 |
| Interest Coverage | 2.38 |
Financial Efficiency
Return on equity (ROE) is 0.60% and return on invested capital (ROIC) is 1.27%.
| Return on Equity (ROE) | 0.60% |
| Return on Assets (ROA) | 1.05% |
| Return on Invested Capital (ROIC) | 1.27% |
| Return on Capital Employed (ROCE) | 1.82% |
| Revenue Per Employee | $362,321 |
| Profits Per Employee | $1,406 |
| Employee Count | 1,000 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 10.69 |
Taxes
In the past 12 months, GeneDx Holdings has paid $130,000 in taxes.
| Income Tax | 130,000 |
| Effective Tax Rate | 8.46% |
Stock Price Statistics
The stock price has increased by +141.25% in the last 52 weeks. The beta is 2.04, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +141.25% |
| 50-Day Moving Average | 118.64 |
| 200-Day Moving Average | 91.44 |
| Relative Strength Index (RSI) | 51.20 |
| Average Volume (20 Days) | 499,771 |
Short Selling Information
The latest short interest is 3.61 million, so 12.57% of the outstanding shares have been sold short.
| Short Interest | 3.61M |
| Short Previous Month | 3.63M |
| Short % of Shares Out | 12.57% |
| Short % of Float | 17.64% |
| Short Ratio (days to cover) | 6.00 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $362.32 million and earned $1.41 million in profits. Earnings per share was $0.05.
| Revenue | 362.32M |
| Gross Profit | 243.42M |
| Operating Income | 7.14M |
| Pretax Income | 1.54M |
| Net Income | 1.41M |
| EBITDA | 29.60M |
| EBIT | 7.14M |
| Earnings Per Share (EPS) | $0.05 |
Balance Sheet
The company has $134.56 million in cash and $114.39 million in debt, giving a net cash position of $20.17 million or $0.70 per share.
| Cash & Cash Equivalents | 134.56M |
| Total Debt | 114.39M |
| Net Cash | 20.17M |
| Net Cash Per Share | $0.70 |
| Equity (Book Value) | 277.13M |
| Book Value Per Share | 9.65 |
| Working Capital | 133.43M |
Cash Flow
In the last 12 months, operating cash flow was $13.02 million and capital expenditures -$12.19 million, giving a free cash flow of $830,000.
| Operating Cash Flow | 13.02M |
| Capital Expenditures | -12.19M |
| Free Cash Flow | 830,000 |
| FCF Per Share | $0.03 |
Margins
Gross margin is 67.18%, with operating and profit margins of 1.97% and 0.39%.
| Gross Margin | 67.18% |
| Operating Margin | 1.97% |
| Pretax Margin | 0.42% |
| Profit Margin | 0.39% |
| EBITDA Margin | 8.17% |
| EBIT Margin | 1.97% |
| FCF Margin | 0.23% |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.34% |
| Shareholder Yield | -9.34% |
| Earnings Yield | 0.04% |
| FCF Yield | 0.02% |
Analyst Forecast
The average price target for GeneDx Holdings is $102.14, which is -15.02% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $102.14 |
| Price Target Difference | -15.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 19.99% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:33 |
Scores
GeneDx Holdings has an Altman Z-Score of 3.06 and a Piotroski F-Score of 8.
| Altman Z-Score | 3.06 |
| Piotroski F-Score | 8 |